| Literature DB >> 30213167 |
Kenji Masuda1, Ko Ebata1, Yoshimasa Yasuhara1, Akira Enomoto1, Tomoyuki Saito2.
Abstract
STUDYEntities:
Keywords: Palliative surgery; Prognosis; Spinal fusion; Spinal instability neoplastic score; Spinal neoplasms
Year: 2018 PMID: 30213167 PMCID: PMC6147881 DOI: 10.31616/asj.2018.12.5.846
Source DB: PubMed Journal: Asian Spine J ISSN: 1976-1902
Spinal Instability Neoplastic Score
| Spinal Instability Neoplastic Score component | Score |
|---|---|
| Location | |
| Junctional (occiput-C2, C7-T2, T11-L1, L5-S1) | 3 |
| Mobile spine (C3-C6, L2-L4) | 2 |
| Semi-rigid (T3-T10) | 1 |
| Rigid (S2-S5) | 0 |
| Pain | |
| Yes | 3 |
| Occasional pain but not mechanical | 1 |
| Pain-free lesion | 0 |
| Bone lesion | |
| Lytic | 2 |
| Mixed (lytic/blastic) | 1 |
| Blastic | 0 |
| Radiographic spinal alignment | |
| Subluxation/translation present | 4 |
| De novo deformity | 2 |
| Normal alignment | 0 |
| Vertebral body collapse | |
| >50% collapse | 3 |
| <50% collapse | 2 |
| No collapse with >50% body involved | 1 |
| None of the above | 0 |
| Posterolateral involvement of spinal elements | |
| Bilateral | 3 |
| Unilateral | 1 |
| None of the above | 0 |
Pain improvement with recumbency and/or pain with movement/loading of spine.
Facet, pedicle, or costovertebral joint fracture or replacement with tumor
The Eastern Cooperative Oncology Group Performance Status grading system
| Grade | Content |
|---|---|
| 0 | Fully active, able to carry out all pre-disease performance without restriction |
| 1 | Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work |
| 2 | Ambulatory and capable of self-care but unable to carry out any work activities up and about >50% of waking hours |
| 3 | Capable of only limited self-care, confined to bed or chair more than 50% of waking hours |
| 4 | Completely disabled, cannot carry out any self-care, totally confined to bed or chair more than 50% of waking hours |
| 5 | Dead |
Comparison of demographic and clinical characteristics of patients in the stable and unstable groups treated with decompression and stabilization for spinal metastases
| Characteristic | Stable group | Unstable group | |
|---|---|---|---|
| Spinal Instability Neoplastic Score | 24 (7-12) | 20 (13-16) | |
| Sex | |||
| Male | 14 (58) | 16 (80) | |
| Female | 10 (42) | 4 (20) | |
| Age at surgery (yr) | 67±9.1 (50-79) | 66±9.5 (47-81) | NS |
| Follow-up period (mo) | 34±36.0 | 21±27.4 | NS |
| Preop Tokuhashi score | 8.2±2.8 | 6.9±3.2 | NS |
| Preop Katagiri score | 4.3±2.0 | 5.2±1.9 | NS |
| Preop Frankel score | 2.8±0.7 | 2.7±0.9 | NS |
| Preop Eastern Cooperative Oncology Group Performance Status | 3.2±0.8 | 3.0±1.1 | NS |
Values are presented as number (range), number (%), mean± SD (range), or mean± SD.
SD, standard deviation; NS, not significant; Preop, preoperative.
The Tokuhashi scoring system for the preoperative evaluation of metastatic spine tumor prognosis
| Prognostic factor | Score |
|---|---|
| General condition (performance status according to Karnofsky) | |
| Poor (10%-40%) | 0 |
| Moderate (50%-70%) | 1 |
| Good (80%-100%) | 2 |
| No. of extraspinal bone metastatic foci | |
| ≥3 | 0 |
| 1-2 | 1 |
| 0 | 2 |
| No. of metastases in the vertebral bodies | |
| ≥3 | 0 |
| 2 | 1 |
| 1 | 2 |
| Metastases to the major internal organs | |
| Irremovable | 0 |
| Removable | 1 |
| No metastases | 2 |
| Primary site of cancer | |
| Lung, stomach | 0 |
| Kidney, liver, uterus, unidentified, other | 1 |
| Thyroid, prostate, breast, rectum | 2 |
| Spinal cord palsy | |
| Complete | 0 |
| Incomplete | 1 |
| None | 2 |
Interpretation of the Tokuhashi score: 9–12, radical surgery; 6–8, clinical judgment; 0–5, palliative management.
The Katagiri scoring system for patients with skeletal metastasis
| Prognostic factor | Score |
|---|---|
| Primary site | |
| Slow growth: hormone-dependent breast and prostate cancer, thyroid cancer, multiple myeloma, and malignant lymphoma | 0 |
| Moderate growth: lung cancer treated with molecularly targeted drugs, hormone-independent breast and prostate cancer, renal cell carcinoma, endometrial and ovarian cancer, sarcoma, and others | 2 |
| Rapid growth: lung cancer without molecularly targeted drugs, colorectal cancer, gastric cancer, pancreatic cancer, head and neck cancer, esophageal cancer, other urological cancer, melanoma, hepatocellular carcinoma, gall bladder cancer, cervical cancer, and cancers of unknown origin | 3 |
| Visceral metastasis | |
| Nodular visceral or cerebral metastasis | 1 |
| Disseminated metastasis | 2 |
| Laboratory data | |
| Abnormal | 1 |
| Critical | 2 |
| Eastern Cooperative Oncology Group Performance Status: 3 or 4 | 1 |
| Previous chemotherapy | 1 |
| Multiple skeletal metastases | 1 |
| Total | 10 |
Pleural, peritoneal, or leptomeningeal dissemination.
C-reactive protein ≥0.4 mg/dL, lactate dehydrogenase ≥250 IU/L, or serum albumin <3.7 g/dL.
Platelets <100,000/μL, serum calcium ≥10.3 mg/dL, or total bilirubin ≥1.4.
Fig. 1.The improvements of Frankel score. The Frankel score improved significantly in both groups.
Fig. 2.The improvements of ECOG-PS. The ECOG-PS score improved significantly in both groups. ECOG-PS, Eastern Cooperative Oncology Group Performance Status.
Fig. 3.Kaplan-Meier survival curve for SINS. There was a statistically significant difference in median survival between the two groups. SINS, Spinal Instability Neoplastic Score.
Fig. 4.Kaplan-Meier survival curve for Katagiri score. There was a statistically significant difference in median survival between the two groups.
Fig. 5.Kaplan-Meier survival curve for Tokuhashi score. There was no statistically significant difference in median survival between the two groups.